Status:

RECRUITING

SYNERGIC-2 Trial (SYNchronizing, Exercises and Remedies to GaIn Cognition@home)

Lead Sponsor:

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Conditions:

Mild Cognitive Impairment

Eligibility:

All Genders

60-85 years

Phase:

NA

Brief Summary

In Canada, 1,700,000 adults are at risk of dementia, half of them with MCI,representing one of the largest groups at risk for an incurable disease. Epidemiological evidence suggests up to 40% of demen...

Detailed Description

Epidemiological evidence suggests up to 40% of potential dementia cases might be preventable by targeting modifiable lifestyle and cardiovascular factors; given that current treatments cannot modify t...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Ages 60-85 years.
  • Having mild cognitive impairment (MCI) defined as meeting all of the following:
  • Presence of subjective memory complaints from the participant and/or informant.
  • Objective impairment on cognitive tests independent of outcome measures.†
  • Preserved activities of daily living assessed (\>14/23 in Lawton-Brody IADL score). For the study, impairment of daily living will be assessed based on cognitive abilities, not physical abilities.
  • Absence of clinical dementia per DSM-IV criteria †Objective cognitive impairment is operationalized as: Montreal Cognitive Assessment (MoCA) total score between 16 and 25 (inclusive), and/or RAVLT delayed recall ≤6, and /or Clinical Dementia Rating Scale (CDR) =0.5
  • Have ≥1 additional dementia risk factors targeted by our intervention as follows: low physical activity (less than 150 minutes of moderate-to-vigorous-intensity physical activity per week, as per GAQ), poor diet (14-item Mediterranean Diet Assessment (MDA-14) score ≤7), insomnia or subthreshold insomnia ( Insomnia Severity Index (ISI) score \>7), and vascular-metabolic risk (Cardiovascular Risk Factors Aging and Incidence of Dementia (CAIDE) score ≥6 and/or diabetes (type I or II) and/or obesity (BMI≥30) and/or diagnosis of high blood pressure (hypertension) and/or smoking).
  • Have access to a home computer/laptop/tablet with home internet (have regular access to email) and ability to use technology (able to send and receive emails and join video conferences).
  • Self-reported levels of proficiency in English for speaking and understanding spoken and written language.
  • Have normal/corrected to normal vision in at least one eye to identify stimuli on computer/tablet screen.
  • Have normal to corrected hearing ability, in order for the participant to engage in digital/virtual communication. Research personnel will determine and assess the hearing ability as per participant's performance.
  • Able to comply with virtual visits, treatment plan, and trial-related activities.
  • Ability to participate in the study's exercise training as determined by the Get Active Questionnaire (GAQ).
  • Exclusion Criteria
  • Having a diagnosis of dementia (based on DSM-IV criteria).
  • Underlying severe disease that precludes engagement with interventions, including presence of psychiatric diagnoses (i.e., major depression (Geriatric Depression Scale (GDS-30) \>19), schizophrenia, severe anxiety, neurological disorder with severe motor deficits, such as current parkinsonism or any neurological disorder with residual severe motor deficits (i.e., stroke with motor deficit), or presence of unstable (non-controlled e.g., symptoms that suggest instability or no treatment for their condition) chronic disease such as congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD) that may preclude the participant from engaging properly with the trial interventions, or advanced-stage active cancer that at the study physician's discretion will prevent them from participating.
  • Having had surgery within the last 2 months or having an upcoming planned surgery in the next 12 months that could interfere with the participant's vision, hearing, mobility, or any other abilities to participate in the study.
  • Regular use of Benzodiazepine or neuroleptic drugs that may interfere with the participants ability to participate in the assessments and interventions.
  • Recent (in the past 12 months) and/or current substance or alcohol abuse.
  • Having had a transmural myocardial infarction (severe heart attack) within six months prior to enrollment in the clinical trial that according to the study physician may preclude physical activity performance.
  • Intention to enroll in other interventional clinical trials during same time.

Exclusion

    Key Trial Info

    Start Date :

    June 5 2023

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 30 2026

    Estimated Enrollment :

    275 Patients enrolled

    Trial Details

    Trial ID

    NCT05375513

    Start Date

    June 5 2023

    End Date

    December 30 2026

    Last Update

    October 29 2024

    Active Locations (8)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (8 locations)

    1

    University of Alberta

    Edmonton, Alberta, Canada, T6G 2G3

    2

    University of British Columbia

    Vancouver, British Columbia, Canada

    3

    University of New Brunswick

    Fredericton, New Brunswick, Canada

    4

    St. Joseph's Health Care London, Parkwood Hospital

    London, Ontario, Canada, N6C5J1